XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.3
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Summary of Stock Option Activity
A summary of stock option activity under the 2012 Plan and the 2021 Plan, including 1.1 million stock options that were granted outside of the 2012 Plan in 2019, is presented below (in millions, except share and per share amounts):
 Number of
Options
Weighted Average
Exercise Price
Weighted Average
Remaining
Contract Term
(in years)
Aggregate Intrinsic Value (1)
Balance as of December 31, 2023
40,527,848 $5.60 5.1$20.2 
Granted— — 
Exercised(3,258,748)1.83 
Forfeited(1,904,614)6.62 
Balance as of September 30, 2024
35,364,486 $5.89 4.6$38.8 
Exercisable and vested at September 30, 2024
32,751,775 $5.64 4.5$38.3 
(1)The aggregate intrinsic values have been calculated using the Company’s closing stock prices of $6.11 and $3.76 as of September 30, 2024 and December 31, 2023, respectively.
Summary of Restricted Stock Units Activity
A summary of RSU activity under the 2012 Plan and the 2021 Plan is presented below:
 Number of AwardsWeighted Average Grant Date Fair Value
Balance as of December 31, 2023
29,943,818 $5.15 
Granted24,238,196 3.62 
Vested and converted to common stock (1)
(18,204,182)4.35 
Forfeited(3,111,621)4.61 
Balance as of September 30, 2024
32,866,211 $4.52 
(1)During the nine months ended September 30, 2024, the Company net settled all RSUs through which it issued an aggregate of 18.2 million shares of Class A common stock and withheld an aggregate of 6.1 million shares of Class A common stock to satisfy $21.8 million of tax withholding obligations on behalf of the Company’s employees.
Summary of Share-based Payment Arrangement, Expensed and Capitalized, Amount
Total stock-based compensation expense included in the condensed consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023 is as follows (in millions):
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Commissions and other related expense$— $— $— $11.6 
Sales and marketing7.8 8.8 24.0 26.4 
Operations and support4.2 4.5 12.3 11.6 
Research and development14.6 11.4 44.7 34.4 
General and administrative5.9 13.3 15.3 37.9 
Total stock-based compensation expense$32.5 $38.0 $96.3 $121.9